NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 54 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $16,000 | +33.3% | 116,100 | 0.0% | 0.00% | – |
| Q4 2018 | $12,000 | -55.6% | 116,100 | 0.0% | 0.00% | – |
| Q3 2018 | $27,000 | 0.0% | 116,100 | 0.0% | 0.00% | – |
| Q2 2018 | $27,000 | -35.7% | 116,100 | 0.0% | 0.00% | – |
| Q1 2018 | $42,000 | 0.0% | 116,100 | 0.0% | 0.00% | – |
| Q4 2017 | $42,000 | -12.5% | 116,100 | 0.0% | 0.00% | – |
| Q3 2017 | $48,000 | -18.6% | 116,100 | 0.0% | 0.00% | – |
| Q2 2017 | $59,000 | -11.9% | 116,100 | 0.0% | 0.00% | – |
| Q1 2017 | $67,000 | -10.7% | 116,100 | -0.9% | 0.00% | – |
| Q4 2016 | $75,000 | -35.9% | 117,100 | -8.1% | 0.00% | -100.0% |
| Q3 2016 | $117,000 | +74.6% | 127,400 | +0.8% | 0.00% | – |
| Q2 2016 | $67,000 | -43.7% | 126,400 | +0.1% | 0.00% | -100.0% |
| Q1 2016 | $119,000 | -29.2% | 126,300 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $168,000 | -41.7% | 126,300 | 0.0% | 0.00% | -66.7% |
| Q3 2015 | $288,000 | +41.9% | 126,300 | 0.0% | 0.00% | +50.0% |
| Q2 2015 | $203,000 | +21.6% | 126,300 | +20.3% | 0.00% | 0.0% |
| Q1 2015 | $167,000 | -15.7% | 105,000 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $198,000 | +42.4% | 105,000 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $139,000 | -10.3% | 105,000 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $155,000 | -20.1% | 105,000 | 0.0% | 0.00% | -33.3% |
| Q1 2014 | $194,000 | -10.6% | 105,000 | 0.0% | 0.00% | -25.0% |
| Q4 2013 | $217,000 | -19.6% | 105,000 | +2.9% | 0.00% | -20.0% |
| Q3 2013 | $270,000 | +39.9% | 102,000 | +41.1% | 0.01% | +25.0% |
| Q2 2013 | $193,000 | – | 72,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |